MedTrace Logo

Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension

NCT00376636 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2007-10-30

No results posted yet for this study

Summary

This study is conducted to investigate the effect of the oral renin inhibitor SPP635 on blood pressure in patients with mild to moderate hypertension.

Conditions

Interventions

DRUG

SPP635 (drug)

Sponsors & Collaborators

  • Speedel Pharma Ltd.

    lead INDUSTRY

Principal Investigators

  • Sybille Baumann-Noss, MD · IKP Bobenheim GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Completion
2007-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00376636 on ClinicalTrials.gov